Lauren Cowell
Acute Care · New Bern, NCNPI 1477146090
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 558 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 25.0% of the total. Among acute care clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 558 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Sanofi$1K
- Johnson & Johnson$1K
- Novartis$984
- Regeneron Healthcare Solutions, Inc.$686
- LEO Pharma Inc.$682
- plus $3K from 17 others
What the payments were for
- Food & beverage$9,29992%
- Education$8078%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 173 | $2,525 |
| Sanofi | 49 | $1,224 |
| Johnson & Johnson | 61 | $1,194 |
| Novartis | 48 | $984 |
| Regeneron Healthcare Solutions, Inc. | 27 | $686 |
| LEO Pharma Inc. | 40 | $682 |
| Pfizer | 45 | $602 |
| Sun Pharmaceutical Industries Inc. | 24 | $561 |
| E.r. Squibb & Sons, L.L.C. | 26 | $429 |
| UCB, Inc. | 14 | $309 |
| Genentech USA, Inc. | 15 | $213 |
| Biofrontera Inc. | 6 | $109 |
| Lilly USA, LLC | 5 | $94 |
| Amgen | 4 | $91 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Organon | 6 | $74 |
| Galderma Laboratories, L.p. | 5 | $68 |
| Almirall LLC | 2 | $40 |
| Boston Scientific | 1 | $36 |
| Incyte Corporation | 2 | $35 |
| Boehringer Ingelheim | 2 | $28 |
| VYNE Pharmaceuticals Inc. | 1 | $27 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
How this compares
$10,106 in reported general payments places this provider in the 95th percentile of 312 acute care providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 98 | $377,049 |
| Cosentyx Unoready PenSecukinumab | 15 | $133,796 |
| OtezlaApremilast | 23 | $111,589 |
| AdbryTralokinumab-Ldrm | 25 | $94,225 |
| Clobetasol Propionate | 390 | $15,883 |
| Tacrolimus | 46 | $6,000 |
| Betamethasone Dipropionate | 54 | $2,794 |
| Metronidazole | 41 | $2,400 |
| Desonide | 35 | $2,262 |
| Tretinoin | 29 | $2,068 |
| CiclopiroxCiclopirox Olamine | 77 | $1,956 |
| Ciclopirox | 39 | $1,658 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 29 | $1,646 |
| Ketoconazole | 94 | $1,581 |
| Doxycycline Hyclate | 79 | $1,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $91 | $111,58923 claims |
| LEO Pharma Inc.Adbry | $682 | $94,22525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 acute care providers in North Carolina.
Other acute care in New Bern
- Dustin GrimesNew Bern$2K
- Benjamin HocuttGreenville$25K
- Matthew KuhnPinehurst$16K
- Robin TruppApex$14K
- Suzanne HartmannRaleigh$12K
- Leigh CasperSalisbury$12K
- Juliana QuagraineCharlotte$11K
- Sarah GroceGreensboro$10K
- Erica TaylorPinehurst$8K
- Kelly BergenGastonia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.